Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

@article{Behr1997PhaseIC,
  title={Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.},
  author={T. M. Behr and Robert M Sharkey and Malik E. Juweid and Robert M. Dunn and R C Vagg and Z. Ying and Chuan Huan Zhang and Lawrence C. Swayne and Yoram Vardi and Jeffry A. Siegel and David M. Goldenberg},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1997},
  volume={38 6},
  pages={858-70}
}
UNLABELLED The aim of this study was to determine, in a Phase I/II clinical trial, the pharmacokinetics, dosimetry and toxicity, as well as antitumor activity, of the 131I-labeled murine anti-carcinoembryonic antigen (CEA) monoclonal antibody, NP-4 (IgG1 subtype). METHODS A total of 57 patients with CEA-expressing tumors (29 colorectal, 9 lung, 7 pancreas, 6 breast and 4 medullary thyroid cancer patients), mostly in very advanced stages, were treated. The patients underwent a diagnostic study… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Tumor Models in Cancer Research

Cancer Drug Discovery and Development • 2002
View 10 Excerpts
Highly Influenced

Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies

European Journal of Nuclear Medicine and Molecular Imaging • 2011
View 2 Excerpts

Similar Papers

Loading similar papers…